OriCAR-017 Clinical Trials
2 recruitingBiologic
Phase 12Phase 21
Showing 1–2 of 2 trials
Recruiting
Phase 1
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NeoplasmsMultiple MyelomaCardiovascular Diseases+11 more
OriCell Therapeutics Co., Ltd.81 enrolled1 locationNCT06271252
Recruiting
Phase 1Phase 2
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Relapsed and/or Refractory Multiple Myeloma
OriCell Therapeutics Co., Ltd.83 enrolled5 locationsNCT06182696